This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Cogent Biosciences, Inc. (COGT) points to a 78.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Cogent Biosciences, Inc. (COGT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's What Could Help Cogent Biosciences, Inc. (COGT) Maintain Its Recent Price Strength
by Zacks Equity Research
Cogent Biosciences, Inc. (COGT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
by Zacks Equity Research
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
by Zacks Equity Research
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
Company News for Jun 13, 2022
by Zacks Equity Research
Companies In The News Are: DOCU, COGT, BA, SFIX.
Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for November 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for November 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Can the Rally in Cogint (COGT) Shares Continue?
by Zacks Equity Research
Cogint, Inc. (COGT) has been on the move lately as the stock has risen by 17.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
Should You Buy Cogint (COGT) Ahead of Earnings?
by Zacks Equity Research
Cogint (COGT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Cogint, Inc. (COGT) Jumps: Stock Rises 6.9%
by Zacks Equity Research
Cogint, Inc. (COGT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.
Falling Earnings Estimates Signal Weakness Ahead for Cogint (COGT)
by Zacks Equity Research
It seems to be a wise decision for investors to drop Cogint (COGT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
Can IDI (COGT) Run Higher on Strong Earnings Estimate Revisions?
by Anupama Mukhopadhyay
On the back of solid estimate revisions, investors may definitely want to consider this Zacks Rank #2 IDI (COGT) stock to profit in the near future.
Cogint (COGT): An Off-the-Radar Potential Winner
by Zacks Equity Research
Cogint (COGT) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Acxiom Teams Up with Verve to Boost Mobile-based Marketing
by Zacks Equity Research
Acxiom (ACXM), a formidable player in the field of marketing services and technology, has announced a partnership with Verve, for location-powered mobile marketing.